News

Enlarge image

ResearchNorway

Algeta partners with Avipep

12.06.2013 - Norway’s cancer radiotherapy specialist Algeta has signed an agreement with Australian antibody developer Avipep Pty Ltd.

Under the terms of the agreement, the Algeta ASA will evaluate a conjugate that couples the Oslo-based company’s alpha-emitter thorium-227 to Avipep’s  Avibody, which targets a number of different solid tumour types. The thorium payload, which triggers DNA double-strand breaks that lead to cell death, have been shown to be highly localised, minimising off-target effects. Algeta has coupled the radionuclide to different cancer-targeting molecules such as Her2 and PDGFRβ

Avipep will provide access to one of its proprietary Avibodies, which the company uses for targeting and labelling tumour cells. Algeta will provide access to chelation and conjugation technologies, as well as to its alpha particle-emitting payload thorium-227. Both companies will contribute financially to the collaboration, which is expected to last for up to one year initially with the option for further cooperation thereafter. No further terms have been disclosed.  Algeta runs already collaborations with Genzyme and Affibody AB to develop Targeted Thorium Conjugates (TTC). After having brought its alpha-emitter radium-223 dichloride to the market, the company now seeks to evaluate targeted approaches of its technology. In contrast to cytotoxic payloads, TTC’s offer the advantage of not being subject to drug resistance.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/algeta-partners-with-avipep.html

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Berlin (GER)

XIV. BIONNALE 2016

Aachen

Biomedica 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • RENEURON (UK)3.50 GBP7.69%

FLOP

  • KAROLINSKA (S)8.00 SEK-8.05%
  • NOVACYT (F)1.50 EUR-7.98%
  • UCB (B)62.79 EUR-7.55%

TOP

  • GENMAB (DK)1229.00 DKK26.7%
  • GALAPAGOS (B)50.94 EUR25.8%
  • NICOX (F)10.97 EUR24.7%

FLOP

  • MOBERG PHARMA (S)38.40 SEK-25.4%
  • BIONOR PHARMA (N)0.69 NOK-24.2%
  • BIOCARTIS GROUP NV (B)8.20 EUR-24.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.20 SEK1872.0%
  • NICOX (F)10.97 EUR496.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-87.6%
  • BB BIOTECH (D)44.27 EUR-84.8%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 24.05.2016